[go: up one dir, main page]

GB201714027D0 - Antisense oligonucleotides for the treatment of huntington's disease - Google Patents

Antisense oligonucleotides for the treatment of huntington's disease

Info

Publication number
GB201714027D0
GB201714027D0 GBGB1714027.8A GB201714027A GB201714027D0 GB 201714027 D0 GB201714027 D0 GB 201714027D0 GB 201714027 A GB201714027 A GB 201714027A GB 201714027 D0 GB201714027 D0 GB 201714027D0
Authority
GB
United Kingdom
Prior art keywords
huntington
disease
treatment
antisense oligonucleotides
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1714027.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ProQR Therapeutics II BV
Original Assignee
ProQR Therapeutics II BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ProQR Therapeutics II BV filed Critical ProQR Therapeutics II BV
Priority to GBGB1714027.8A priority Critical patent/GB201714027D0/en
Publication of GB201714027D0 publication Critical patent/GB201714027D0/en
Priority to PCT/EP2018/073175 priority patent/WO2019043027A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1714027.8A 2017-09-01 2017-09-01 Antisense oligonucleotides for the treatment of huntington's disease Ceased GB201714027D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1714027.8A GB201714027D0 (en) 2017-09-01 2017-09-01 Antisense oligonucleotides for the treatment of huntington's disease
PCT/EP2018/073175 WO2019043027A1 (en) 2017-09-01 2018-08-29 Antisense oligonucleotides for the treatment of huntington's disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1714027.8A GB201714027D0 (en) 2017-09-01 2017-09-01 Antisense oligonucleotides for the treatment of huntington's disease

Publications (1)

Publication Number Publication Date
GB201714027D0 true GB201714027D0 (en) 2017-10-18

Family

ID=60050535

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1714027.8A Ceased GB201714027D0 (en) 2017-09-01 2017-09-01 Antisense oligonucleotides for the treatment of huntington's disease

Country Status (2)

Country Link
GB (1) GB201714027D0 (en)
WO (1) WO2019043027A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230145206A (en) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. Modulatory polynucleotides
JP7220080B2 (en) 2016-05-18 2023-02-09 ボイジャー セラピューティクス インコーポレイテッド Compositions and methods for treating Huntington's disease
KR102652994B1 (en) 2016-05-18 2024-04-01 보이저 테라퓨틱스, 인크. Modulatory polynucleotides
EP3475424A1 (en) 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
DK3507366T3 (en) 2016-09-01 2020-11-02 Proqr Therapeutics Ii Bv CHEMICAL MODIFIED, SINGLE STRANDED RNA-MODIFYING OLIGONUCLEOTIDES
SG11201909868YA (en) 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
EP4069842A1 (en) 2019-12-02 2022-10-12 Shape Therapeutics Inc. Therapeutic editing
WO2025132708A1 (en) 2023-12-20 2025-06-26 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease
GB202405143D0 (en) 2024-04-11 2024-05-29 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of poly-q disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807187C (en) * 2010-08-05 2019-06-11 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins.
MX2016004452A (en) * 2013-10-07 2017-04-27 Academisch Ziekenhuis Leiden Antisense oligonucleotide directed removal of proteolytic cleavage sites, the hchwa-d mutation, and trinucleotide repeat expansions.

Also Published As

Publication number Publication date
WO2019043027A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
IL265206A (en) Antisense oligonucleotides for the treatment of eye disease
IL271046B1 (en) Compounds for treating huntington's disease
IL281633A (en) Methods for treating huntington's disease
GB201714027D0 (en) Antisense oligonucleotides for the treatment of huntington's disease
IL265528A (en) Aav treatment of huntington's disease
IL277497A (en) Compounds for treating huntington's disease
IL269599A (en) 11,13-modified saxitoxins for the treatment of pain
EP3645121B8 (en) Methods for treating huntington's disease
IL258471A (en) 11,13-modified saxitoxins for the treatment of pain
IL269735A (en) Antisense oligonucleotides for the treatment of Stragradt disease
IL263188B (en) Treatment for parkinson's disease
AU2022271491B2 (en) Antisense oligonucleotides for use in treating alzheimer's disease
PL3285755T3 (en) Creatine hydrochloride for the treatment of huntington's disease
EP3697914C0 (en) Vectors for the treatment of friedreich's ataxia
PT3458045T (en) Treatment of meniere's disease
IL274536A (en) Methods for prognosis or treatment of parkinson's disease
IL268008A (en) Ppargamma agonist for the treatment of huntington's disease
ZA201801945B (en) Compositions and methods for the treatment of parkinson's disease
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
GB201603510D0 (en) Compositions for use in the treatment of neurological disease
ZA201807944B (en) Treatment for parkinson's disease
GB201518052D0 (en) Parkinson's disease treatment
GB201504144D0 (en) Treatment of Parkinson's disease
GB201715763D0 (en) Treatment of neurological disease
GB201705435D0 (en) Treatment of ocular disease

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)